Praxis Precision Medicines (PRAX) Preferred Stock Liabilities (2019)

Praxis Precision Medicines (PRAX) recorded quarterly Preferred Stock Liabilities of $121.1 million in Q4 2019.

Praxis Precision Medicines (PRAX) Preferred Stock Liabilities (2019) Analysis & Trends

Praxis Precision Medicines' Preferred Stock Liabilities history runs 1 years deep, the most recent figure standing at $121.1 million for Q4 2019.

In Q4 2019, Preferred Stock Liabilities changed N/A year-over-year to $121.1 million; the TTM figure through Dec 2019 stood at $121.1 million (changed N/A YoY), while the FY2019 annual figure was $121.1 million, changed N/A from the prior year.
Preferred Stock Liabilities was $121.1 million for Q4 2019 at Praxis Precision Medicines.
In the past five years, Preferred Stock Liabilities ranged from a high of $121.1 million in Q4 2019 to a low of $121.1 million in Q4 2019.

#	Company	Market Cap	Enterprise Value	Gross Profit (Qtr)	Preferred Stock Liabilities (Qtr)
1	Alterity Therapeutics	925,601.88 Bn	925,601.85 Bn	-	-
2	Belite Bio	58,560.00 Bn	58,560.00 Bn	-	-
3	Quantum Biopharma	17,284.41 Bn	17,284.40 Bn	-	-
4	Legend Biotech	2,809.00 Bn	2,808.71 Bn	242.10 Mn	-
5	Evaxion A	1,334.43 Bn	1,334.42 Bn	-	-
6	Akari Therapeutics	1,312.27 Bn	1,312.26 Bn	-	-
7	Psyence Biomedical	212.16 Bn	212.16 Bn	-	-
8	Vertex Pharmaceuticals	114.83 Bn	107.58 Bn	2.59 Bn	-
9	Abivax	91.96 Bn	91.96 Bn	-	-
10	Praxis Precision Medicines	200.22 Mn	-586.65 Mn	-	-

Download Data

Date	Value
Dec 31, 2019	121.12 Mn